{"url_path":"/sec/arct/8-k/2026-06-05/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1768224/0001193805-26-000770-index.html","accession_number":"0001193805-26-000770","cik":"0001768224","ticker":"ARCT","issuer_name":"Arcturus Therapeutics Holdings Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1768224/0001193805-26-000770-index.html","primary_entity_key":"0001768224","primary_entity_name":"Arcturus Therapeutics Holdings Inc."},"word_count":310,"has_tables":true,"body_markdown":"false\n0001768224\n\n0001768224\n\n2026-06-05\n2026-06-05\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act\nof 1934**\n\n \n\n**Date of Report (Date of earliest\nevent reported): June 5, 2026**\n\n  \n\n**ARCTURUS THERAPEUTICS HOLDINGS\nINC.**\n\n**(Exact name of registrant as\nspecified in its charter)**\n\n \n\n**Delaware**\n \n**001-38942**\n \n**32-0595345**\n\n**(State or other jurisdiction\nof incorporation)**\n \n**(Commission\nFile Number)**\n \n**(I.R.S. Employer\nIdentification No.)**\n\n \n\n**10285 Science Center Drive**\n\n**San Diego, California 92121**\n\n**(Address of principal executive\noffices)**\n\n \n\n**Registrant’s telephone\nnumber, including area code: (858) 900-2660**\n\n \n\n**(Former name or former address,\nif changed since last report)**\n\n \n\nCheck the appropriate box below if the Form 8-K filing\nis intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of\nthe Act:\n\n \n\n**Title of each class**\n \n\n**Trading**\n\n**Symbol(s)**\n\n \n**Name of each exchange\non which registered**\n\n**Common stock, par value $0.001 per share**\n \n**ARCT**\n \n**The NASDAQ Stock Market LLC**\n\n    \n\nIndicate by check mark whether\nthe registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule\n12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company,\nindicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}